Backgroound The best treatment for patients with “hormone-refractory” metastatic prostate
cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed …

The effect of flutamide withdrawal was studied in 40 patients with stage D2 prostate cancer
showing progression of the disease after an initial and long (average 3.9 years) period of …

A phase I study of orally administered flutamide (a pure anti-androgen) was performed in 26
patients with prostatic cancer. No side effects were observed in 11 patients receiving single …

The efficacy of combined androgen blockade therapy consisting of flutamide, a nonsteroidal
antiandrogen, plus an LH-RH agonist (F-CAB) was investigated in Japanese patients with …

The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical
doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone …

Synopsis Flutamide, a nonsteroidal antiandrogenic drug devoid of hormonal agonist activity,
is used in the treatment of advanced prostate cancer. In previously untreated patients …

METHODS All patients were required to give informed consent prior to participation in this
protocol. Histologic diagnosis of prostate cancer was confinned at our in-stitution before …

Little is known about the efficacy of flutamide monotherapy in previously untreated patients
with prostatic carcinoma. In this study, 40 patients with advanced disease were treated with …

Objectives: This trial was designed to compare the efficacy of Flutamide (FLU) versus
Cyproterone acetate (CPA) in men with metastatic prostate cancer and favourable …

In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible
patients with newly diagnosed disseminated adenocarcinoma of the prostate were …